

Resource Summary Report

Generated by [RRID](#) on Aug 2, 2026

PE/Cyanine7 anti-mouse CD69

RRID:AB_493564

Type: Antibody

Proper Citation

BioLegend Cat# 104512, RRID:AB_493564

Antibody Information

URL: http://antibodyregistry.org/AB_493564

Proper Citation: BioLegend Cat# 104512, RRID:AB_493564

Target Antigen: CD69

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-mouse CD69

Description: This monoclonal targets CD69

Target Organism: mouse

Clone ID: Clone H1.2F3

Antibody ID: AB_493564

Vendor: BioLegend

Catalog Number: 104512

Alternative Catalog Numbers: 104511

Record Creation Time: 20250819T214358+0000

Record Last Update: 20250819T235523+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-mouse CD69.

No alerts have been found for PE/Cyanine7 anti-mouse CD69.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 54 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Song B, et al. (2025) Histotripsy-Focused Ultrasound Treatment Abrogates Tumor Hypoxia Responses and Stimulates Antitumor Immune Responses in Melanoma. *Molecular cancer therapeutics*, 24(7), 1088.

Chen KY, et al. (2025) Inflammation switches the chemoattractant requirements for naive lymphocyte entry into lymph nodes. *Cell*, 188(4), 1019.

Guo C, et al. (2025) In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence. *Cell reports. Medicine*, 6(10), 102399.

Tripathi A, et al. (2025) Nrf2 drives activation-driven expansion of CD4+T cells by modulating glucose and glutamine metabolism. *Cell reports*, 44(9), 116177.

Dijkstra M, et al. (2025) Albumin-targeted oxaliplatin(iv) prodrugs bearing STING agonists. *Inorganic chemistry frontiers*, 12(13), 4284.

Zhou Y, et al. (2025) Glucose-1-phosphate promotes compartmentalization of glycogen with the pentose phosphate pathway in CD8+ memory T cells. *Molecular cell*, 85(13), 2535.

Barandun N, et al. (2025) Targeted localization of the mother centrosome in CD8+ T cells undergoing asymmetric cell division promotes memory formation. *Cell reports*, 44(1), 115127.

Chen L, et al. (2025) CD94/NKG2A-Qa-1b axis as a key modulator of vaccine responsiveness in aging populations. *Cell reports*, 44(11), 116514.

He C, et al. (2025) The balance between conventional and unconventional T follicular helper cells influences autoreactive B cell responses. *Cell reports*, 44(5), 115602.

Syed F, et al. (2025) Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in mice. *EBioMedicine*, 117, 105734.

Zhang Y, et al. (2025) Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer. *Cancer cell*, 43(9), 1677.

Zhang Z, et al. (2025) Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. *Cell reports. Medicine*, 6(7), 102209.

Gao Q, et al. (2025) Remodeling of T and endothelial cells during total neoadjuvant therapy in rectal cancer. *Cancer cell*, 43(12), 2282.

Torcellan T, et al. (2024) Circulating NK cells establish tissue residency upon acute infection of skin and mediate accelerated effector responses to secondary infection. *Immunity*, 57(1), 124.

Fang Q, et al. (2024) Gingival-derived mesenchymal stem cells alleviate allergic asthma inflammation via HGF in animal models. *iScience*, 27(5), 109818.

Ran L, et al. (2024) The transcription regulator ID3 maintains tumor-specific memory CD8⁺ T cells in draining lymph nodes during tumorigenesis. *Cell reports*, 43(9), 114690.

Wang H, et al. (2024) Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer. *Med (New York, N.Y.)*, 5(10), 1237.

Peeters JGC, et al. (2024) Hyperactivating EZH2 to augment H3K27me3 levels in regulatory T cells enhances immune suppression by driving early effector differentiation. *Cell reports*, 43(9), 114724.

Liu K, et al. (2024) Thymosin α 1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy. *Cell reports. Medicine*, 5(10), 101751.

Ngiow SF, et al. (2024) LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. *Cell*, 187(16), 4336.